2017 American Transplant Congress
A Phase-Two, Randomised, Placebo-Controlled Trial: Belimumab in Renal Transplantation Targets Naïve, Activated Memory and Antibody Producing B Cells Whilst Sparing Regulatory B Cells.
This phase 2, double-blind, randomised controlled study (BEL114424) explores the safety and potential efficacy of addition of belimumab to standard of care in renal transplantation…2017 American Transplant Congress
Tacrolimus Suppresses Calcineurin Activity and Ca2+ Influx Age-Specifically.
Immunosenescence is impacting alloimmunity and outcomes after organ transplantation. Age-dependent effects of immunosuppressants, however, have not been tested sufficiently. Here, we tested the effects of…2017 American Transplant Congress
Tofacitinib-Loaded Solid Lipid Nanoparticles Inhibits Dendritic Cell Antigen Presenting Functions and Achieve Selective In Vivo Targeting.
BackgroundComplications from long-term use of calcineurin inhibitors are a major concern for transplant patients. To develop CNI-free therapies, we investigated an innovative drug delivery method…2017 American Transplant Congress
Infections and Outcomes in Renal Transplantation Patients Using Alemtuzumab for Induction Immunosuppression: Preliminary Results.
Surgery, University of Toledo College of Medicine, Toledo, OH
Introduction: Alemtuzumab (Ale) is a monoclonal antibody targeting CD52+ lympocytes. We sought to determine the impact of Ale immunodepletion, with steroid freedom for low risk…2017 American Transplant Congress
Immunosuppressive Therapy and Acute Rejection in Combined Heart and Kidney Transplantation.
University of Louisville, Louisville
Background. This study evaluated the management of immunosuppressive therapy and the incidence of acute heart rejection within 1 year from concomitant heart-kidney transplantation (cHTKx) compared…2017 American Transplant Congress
In Vitro Optimisation of the Immunotherapeutic Effects of Umbilical Cord Derived MSC.
Mesenchymal stromal cells (MSC) possess immunomodulatory properties and are low immunogenic, which are both important for their development into an effective cellular immunotherapy after organ…2017 American Transplant Congress
Population Pharmacokinetic Profiling of Tacrolimus in Renal Transplant Recipients (RTRs) Taking Diltiazem.
Background: Over the past 6 years we have prospectively used pharmacokinetic (PK) profiling of Tacrolimus (TAC) in “stable” RTR's to individualise future dosing. This study…2017 American Transplant Congress
Evaluation of the Conversion from Brand Name to Generic Immunosuppression in Hospitalized Organ Transplant Recipients.
Purpose: Safe and effective immunosuppressant medications are critical to accomplish good graft and patient survival rates. The availability of “AB-rated” generic immunosuppression affords the opportunity…2017 American Transplant Congress
Evaluation of Renal Function After a Transition to Everolimus or Mycophenolate Mofetil in Liver Transplant Recipients.
Purpose: The aim of this study was to assess if there is a difference in renal function over time when transitioning to everolimus vs. mycophenolate.Methods:…2017 American Transplant Congress
A Search for a Biomarker Which Predicts Belatacept-Resistant Rejection.
Belatacept, an inhibitor of the CD28-CD80/86 costimulatory pathway, has been associated with a higher acute rejection risk than ciclosporin. We sought to identify a biomarker…
- « Previous Page
- 1
- …
- 98
- 99
- 100
- 101
- 102
- …
- 138
- Next Page »